Annual FCF:
$178.75M+$39.27M(+28.15%)Summary
- As of today, PCRX annual free cash flow is $178.75 million, with the most recent change of +$39.27 million (+28.15%) on December 31, 2024.
- During the last 3 years, PCRX annual free cash flow has risen by +$98.90 million (+123.86%).
- PCRX annual free cash flow is now at all-time high.
Performance
PCRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly FCF:
$9.31M-$17.60M(-65.39%)Summary
- As of today, PCRX quarterly free cash flow is $9.31 million, with the most recent change of -$17.60 million (-65.39%) on June 30, 2025.
- Over the past year, PCRX quarterly free cash flow has dropped by -$42.33 million (-81.96%).
- PCRX quarterly free cash flow is now -81.96% below its all-time high of $51.65 million, reached on June 30, 2024.
Performance
PCRX Quarterly Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
$117.07M-$42.33M(-26.56%)Summary
- As of today, PCRX TTM free cash flow is $117.07 million, with the most recent change of -$42.33 million (-26.56%) on June 30, 2025.
- Over the past year, PCRX TTM free cash flow has dropped by -$67.67 million (-36.63%).
- PCRX TTM free cash flow is now -39.51% below its all-time high of $193.53 million, reached on September 30, 2024.
Performance
PCRX TTM Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
PCRX Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +28.1% | -82.0% | -36.6% |
| 3Y3 Years | +123.9% | -48.5% | +14.3% |
| 5Y5 Years | +196.1% | +138.0% | +312.5% |
PCRX Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +123.9% | -82.0% | at low | -39.5% | +26.3% |
| 5Y | 5-Year | at high | +355.6% | -82.0% | +1039.0% | -39.5% | +312.5% |
| All-Time | All-Time | at high | +304.7% | -82.0% | +137.5% | -39.5% | +234.1% |
PCRX Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $9.31M(-65.4%) | $117.07M(-26.6%) |
| Mar 2025 | - | $26.91M(-13.2%) | $159.40M(-10.8%) |
| Dec 2024 | $178.75M(+28.1%) | $31.01M(-37.8%) | $178.75M(-7.6%) |
| Sep 2024 | - | $49.83M(-3.5%) | $193.53M(+4.8%) |
| Jun 2024 | - | $51.65M(+11.6%) | $184.74M(+6.7%) |
| Mar 2024 | - | $46.27M(+1.0%) | $173.19M(+24.2%) |
| Dec 2023 | $139.49M(+21.1%) | $45.79M(+11.6%) | $139.49M(+7.1%) |
| Sep 2023 | - | $41.04M(+2.4%) | $130.25M(+2.8%) |
| Jun 2023 | - | $40.09M(+219.2%) | $126.68M(+21.0%) |
| Mar 2023 | - | $12.56M(-65.6%) | $104.65M(-9.2%) |
| Dec 2022 | $115.20M(+44.3%) | $36.55M(-2.5%) | $115.20M(+24.3%) |
| Sep 2022 | - | $37.47M(+107.4%) | $92.70M(-9.5%) |
| Jun 2022 | - | $18.07M(-21.8%) | $102.44M(-1.5%) |
| Mar 2022 | - | $23.11M(+64.5%) | $103.95M(+30.2%) |
| Dec 2021 | $79.85M(+103.5%) | $14.05M(-70.2%) | $79.85M(-18.6%) |
| Sep 2021 | - | $47.21M(+141.1%) | $98.06M(+18.3%) |
| Jun 2021 | - | $19.58M(+2074.1%) | $82.87M(+113.8%) |
| Mar 2021 | - | -$992.00K(-103.1%) | $38.76M(-1.2%) |
| Dec 2020 | $39.23M(-35.0%) | $32.26M(+0.8%) | $39.23M(+38.2%) |
| Sep 2020 | - | $32.02M(+230.5%) | $28.38M(+116.3%) |
| Jun 2020 | - | -$24.53M(-4653.9%) | $13.12M(-77.5%) |
| Mar 2020 | - | -$516.00K(-102.4%) | $58.36M(-3.3%) |
| Dec 2019 | $60.36M(+75.7%) | $21.41M(+27.7%) | $60.36M(+4.2%) |
| Sep 2019 | - | $16.76M(-19.1%) | $57.93M(+8.6%) |
| Jun 2019 | - | $20.71M(+1298.4%) | $53.34M(+22.0%) |
| Mar 2019 | - | $1.48M(-92.2%) | $43.71M(+27.2%) |
| Dec 2018 | $34.36M(+2419.8%) | $18.98M(+55.9%) | $34.36M(+26.2%) |
| Sep 2018 | - | $12.18M(+9.9%) | $27.23M(+298.7%) |
| Jun 2018 | - | $11.08M(+240.7%) | $6.83M(+218.9%) |
| Mar 2018 | - | -$7.87M(-166.4%) | -$5.74M(-287.8%) |
| Dec 2017 | -$1.48M | $11.86M(+244.1%) | -$1.48M(-70.4%) |
| Sep 2017 | - | -$8.23M(-448.8%) | -$869.00K(-105.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$1.50M(+58.5%) | $15.14M(-1.1%) |
| Mar 2017 | - | -$3.61M(-129.0%) | $15.31M(+75.1%) |
| Dec 2016 | $8.74M(+164.7%) | $12.47M(+60.3%) | $8.74M(+334.9%) |
| Sep 2016 | - | $7.78M(+686.1%) | -$3.72M(+79.6%) |
| Jun 2016 | - | -$1.33M(+87.0%) | -$18.29M(+15.4%) |
| Mar 2016 | - | -$10.17M(-49.9%) | -$21.61M(-40.5%) |
| Dec 2015 | -$13.51M(-396.9%) | - | - |
| Sep 2015 | - | -$6.79M(-45.8%) | -$15.39M(-231.3%) |
| Jun 2015 | - | -$4.65M(+53.4%) | -$4.64M(-201.6%) |
| Mar 2015 | - | -$9.98M(-265.4%) | $4.57M(+0.4%) |
| Dec 2014 | $4.55M(+108.2%) | $6.03M(+52.5%) | $4.55M(+140.6%) |
| Sep 2014 | - | $3.96M(-13.2%) | -$11.21M(+61.7%) |
| Jun 2014 | - | $4.56M(+145.6%) | -$29.24M(+40.3%) |
| Mar 2014 | - | -$10.00M(-2.8%) | -$48.95M(+11.9%) |
| Dec 2013 | -$55.58M(+36.3%) | -$9.72M(+30.9%) | -$55.58M(+21.4%) |
| Sep 2013 | - | -$14.08M(+7.1%) | -$70.69M(+4.5%) |
| Jun 2013 | - | -$15.15M(+8.8%) | -$74.04M(+11.3%) |
| Mar 2013 | - | -$16.62M(+33.1%) | -$83.48M(+4.4%) |
| Dec 2012 | -$87.31M(-134.9%) | -$24.84M(-42.4%) | -$87.31M(-20.3%) |
| Sep 2012 | - | -$17.43M(+29.1%) | -$72.56M(-11.2%) |
| Jun 2012 | - | -$24.59M(-20.3%) | -$65.26M(-23.6%) |
| Mar 2012 | - | -$20.45M(-102.9%) | -$52.79M(-42.0%) |
| Dec 2011 | -$37.17M(-17.4%) | -$10.08M(+0.6%) | -$37.17M(-3.6%) |
| Sep 2011 | - | -$10.14M(+16.4%) | -$35.88M(-3.9%) |
| Jun 2011 | - | -$12.13M(-151.6%) | -$34.55M(-6.4%) |
| Mar 2011 | - | -$4.82M(+45.2%) | -$32.46M(-2.5%) |
| Dec 2010 | -$31.65M(-20.1%) | -$8.79M(+0.3%) | -$31.65M(-38.4%) |
| Sep 2010 | - | -$8.81M(+12.2%) | -$22.86M(-62.7%) |
| Jun 2010 | - | -$10.04M(-150.1%) | -$14.05M(-250.1%) |
| Mar 2010 | - | -$4.01M | -$4.01M |
| Dec 2009 | -$26.35M(+24.8%) | - | - |
| Dec 2008 | -$35.03M(-106.0%) | - | - |
| Dec 2007 | -$17.00M | - | - |
FAQ
- What is Pacira BioSciences, Inc. annual free cash flow?
- What is the all-time high annual free cash flow for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. annual free cash flow year-on-year change?
- What is Pacira BioSciences, Inc. quarterly free cash flow?
- What is the all-time high quarterly free cash flow for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. quarterly free cash flow year-on-year change?
- What is Pacira BioSciences, Inc. TTM free cash flow?
- What is the all-time high TTM free cash flow for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. TTM free cash flow year-on-year change?
What is Pacira BioSciences, Inc. annual free cash flow?
The current annual free cash flow of PCRX is $178.75M
What is the all-time high annual free cash flow for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high annual free cash flow is $178.75M
What is Pacira BioSciences, Inc. annual free cash flow year-on-year change?
Over the past year, PCRX annual free cash flow has changed by +$39.27M (+28.15%)
What is Pacira BioSciences, Inc. quarterly free cash flow?
The current quarterly free cash flow of PCRX is $9.31M
What is the all-time high quarterly free cash flow for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high quarterly free cash flow is $51.65M
What is Pacira BioSciences, Inc. quarterly free cash flow year-on-year change?
Over the past year, PCRX quarterly free cash flow has changed by -$42.33M (-81.96%)
What is Pacira BioSciences, Inc. TTM free cash flow?
The current TTM free cash flow of PCRX is $117.07M
What is the all-time high TTM free cash flow for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high TTM free cash flow is $193.53M
What is Pacira BioSciences, Inc. TTM free cash flow year-on-year change?
Over the past year, PCRX TTM free cash flow has changed by -$67.67M (-36.63%)